A Medical Device Daily

PRA International (Reston, Virginia), a global clinical research organization, reported a proposed public offering of 6 million shares of its common stock, par value 1 cent per share, all of which will be sold by certain stockholders of PRA.

The selling stockholders have granted the underwriters the right to purchase up to an additional 900,000 shares at the public offering price.

The company, which has filed a registration statement with the Securities and Exchange Commission related to the offering, said the timing and the size of the offering would depend on market conditions and other factors.

The offering will be made through an underwriting syndicate led by Credit Suisse First Boston and Bear, Stearns & Co.

Vyteris Holdings (Fair Lawn, New Jersey), formerly Treasure Mounting Holdings, and the parent corporation of Vyteris, said that the SEC has declared effective its registration statement covering 12,960,174 shares of its common stock.

The 12,990,174 shares consist of 7,819,620 outstanding shares and 5,140,554 shares covered by outstanding warrants. The registration statement relates solely to the resale of shares of common stock owned by certain stockholders of the company.

Vyteris Holdings will not receive any proceeds from the sale of shares by the selling stockholders, but will receive proceeds to the extent that such warrants are exercised through cash payments.

Vyteris Holdings is a specialty pharmaceutical company organized to develop pharmaceutical products based upon its advanced drug delivery technology. The company’s Actyve transdermal drug delivery (iontophoresis) technology delivers drugs through the skin using low-level electrical energy. This technology is designed to allow precise dosing.

In other financing activity:

InterGenetics (Oklahoma City), a genetic-based cancer risk testing and treatment company, reported that it closed a $6 million private placement, with the majority of its investors residing in Oklahoma and Texas.

“The successful completion of our private placement offering achieves a major milestone and provides the funding to complete our lab diagnostic facility and commercially launch our first cancer risk test for breast cancer called OncoVue,” said Dr. Craig Shimasaki, president and CEO.

InterGenetics plans to launch OncoVue, which it said is the first genetic-based breast cancer risk predictive test able to determine the lifetime and age-specific risk for dev-eloping breast cancer applicable to all women, this fall.

The company said the test is simple for a woman to perform. First, she completes a brief medical questionnaire and then swishes a mouthwash and deposits the fluid into a tube. DNA from the woman’s cheek cells are analyzed at InterGenetics’ DNA Diagnostic Lab in Oklahoma City along with the data collected from the medical questionnaire to determine a numeric score. This score represents the patient’s risk of developing breast cancer every five years of her life.

Nationwide Health Properties (Newport Beach, California) reported the pricing of $250 million of 6% senior unsecured notes due May 18, 2015. The price to the investors for the notes was 97.769% of the principal amount.

The company said it intends to use the net proceeds of the offering to pay down outstanding indebtedness under its unsecured revolving bank line of credit.

The offering was underwritten by JP Morgan Securities as sole book-running manager. Banc of America Securities, UBS Securities and Wachovia Capital Markets were senior co- managers and Caylon Securities, Cohen & Steers, KeyBanc Capital Markets and Wells Fargo Securities were junior book- running managers:

Nationwide Health Properties is a real estate investment trust that invests in healthcare facilities. The company currently has investments in 424 facilities in 39 states.